INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 42h ago
HOUSE PTR2h ago
SEC 13F2h ago
ROBINHOOD CHAIN2h ago
SEC FORM 4/Open-market saleVerified data

Engelhardt Eva Anette sold BIOBIO.B

EVP, President, CDG · BIO-RAD LABORATORIES, INC. · Bio-Rad A Common Stock

Side
SELL
Value
$136K
Shares
550
Price
$246.54
Executed
May 11, 2026
Disclosed
May 13, 2026
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
May 11 executedMay 13, 2026 disclosed

BIOBIO.B · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
36/ 100 · ELEVATED
Methodology →
  • Transaction type+12 / 20

    Open-market sale

  • Relative size+16 / 25

    $136K reported value · 61.4% of prior position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · BIOBIO.B

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    9
    ES
    Evran SedatEVP, Global Supply Chain
    BIOBIO.BBIO-RAD LABORATORIES, INC.
    Option exercise
    		M—
    1,044 sh
    		Oct 20, 2026Oct 22, 2026
    traded Oct 20, 2026
    		+2dSEC FORM 4

    Evidence

    17
    ES
    Evran SedatEVP, Global Supply Chain
    BIOBIO.BBIO-RAD LABORATORIES, INC.
    Option exercise
    		M—
    1,044 sh
    		Oct 20, 2026Oct 22, 2026
    traded Oct 20, 2026
    		+2dSEC FORM 4

    Evidence

    16
    ES
    Evran SedatEVP, Global Supply Chain
    BIOBIO.BBIO-RAD LABORATORIES, INC.
    Tax withholding
    		F$173K
    487 sh
    		Oct 20, 2026Oct 22, 2026
    traded Oct 20, 2026
    		+2dSEC FORM 4

    Evidence

    23
    ES
    Evran SedatEVP, Global Supply Chain
    BIOBIO.BBIO-RAD LABORATORIES, INC.
    Option exercise
    		M—
    1,027 sh
    		Sep 5, 2026Sep 9, 2026
    traded Sep 5, 2026
    		+4dSEC FORM 4

    Evidence

    22
    ES
    Evran SedatEVP, Global Supply Chain
    BIOBIO.BBIO-RAD LABORATORIES, INC.
    Tax withholding
    		F$127K
    329 sh
    		Sep 5, 2026Sep 9, 2026
    traded Sep 5, 2026
    		+4dSEC FORM 4

    Evidence

    23
    ES
    Evran SedatEVP, Global Supply Chain
    BIOBIO.BBIO-RAD LABORATORIES, INC.
    Option exercise
    		M—
    864 sh
    		Sep 6, 2026Sep 9, 2026
    traded Sep 6, 2026
    		+3dSEC FORM 4

    Evidence

    22
    ES
    Evran SedatEVP, Global Supply Chain
    BIOBIO.BBIO-RAD LABORATORIES, INC.
    Tax withholding
    		F$107K
    277 sh
    		Sep 6, 2026Sep 9, 2026
    traded Sep 6, 2026
    		+3dSEC FORM 4

    Evidence

    15
    ES
    Evran SedatEVP, Global Supply Chain
    BIOBIO.BBIO-RAD LABORATORIES, INC.
    Grant or award
    		A—
    4,026 sh
    		Sep 4, 2026Sep 9, 2026
    traded Sep 4, 2026
    		+5dSEC FORM 4

    Evidence

    23
    ES
    Evran SedatEVP, Global Supply Chain
    BIOBIO.BBIO-RAD LABORATORIES, INC.
    Option exercise
    		M—
    1,027 sh
    		Sep 5, 2026Sep 9, 2026
    traded Sep 5, 2026
    		+4dSEC FORM 4

    Evidence

    27
    ES
    Evran SedatEVP, Global Supply Chain
    BIOBIO.BBIO-RAD LABORATORIES, INC.
    Option exercise
    		M—
    864 sh
    		Sep 6, 2026Sep 9, 2026
    traded Sep 6, 2026
    		+3dSEC FORM 4

    Evidence

    19
    AS
    Allison SchwartzDirector
    BIOBIO.BBIO-RAD LABORATORIES, INC.
    Option exercise
    		M—
    228 sh
    		Sep 5, 2026Sep 9, 2026
    traded Sep 5, 2026
    		+4dSEC FORM 4

    Evidence

    15
    AS
    Allison SchwartzDirector
    BIOBIO.BBIO-RAD LABORATORIES, INC.
    Grant or award
    		A—
    719 sh
    		Sep 4, 2026Sep 9, 2026
    traded Sep 4, 2026
    		+5dSEC FORM 4

    Evidence

    23
    AS
    Allison SchwartzDirector
    BIOBIO.BBIO-RAD LABORATORIES, INC.
    Option exercise
    		M—
    228 sh
    		Sep 5, 2026Sep 9, 2026
    traded Sep 5, 2026
    		+4dSEC FORM 4

    Evidence

    27
    AS
    Allison SchwartzDirector
    BIOBIO.BBIO-RAD LABORATORIES, INC.
    Option exercise
    		M—
    92 sh
    		Sep 6, 2026Sep 9, 2026
    traded Sep 6, 2026
    		+3dSEC FORM 4

    Evidence

    19
    AS
    Allison SchwartzDirector
    BIOBIO.BBIO-RAD LABORATORIES, INC.
    Tax withholding
    		F$32K
    82 sh
    		Sep 5, 2026Sep 9, 2026
    traded Sep 5, 2026
    		+4dSEC FORM 4

    Evidence

    26
    EC
    Enloe Courtney CEVP, General Counsel & Sec
    BIOBIO.BBIO-RAD LABORATORIES, INC.
    Tax withholding
    		F$118K
    305 sh
    		Sep 6, 2026Sep 9, 2026
    traded Sep 6, 2026
    		+3dSEC FORM 4

    Evidence

    19
    AS
    Allison SchwartzDirector
    BIOBIO.BBIO-RAD LABORATORIES, INC.
    Option exercise
    		M—
    92 sh
    		Sep 6, 2026Sep 9, 2026
    traded Sep 6, 2026
    		+3dSEC FORM 4

    Evidence

    15
    AS
    Allison SchwartzDirector
    BIOBIO.BBIO-RAD LABORATORIES, INC.
    Tax withholding
    		F$13K
    34 sh
    		Sep 6, 2026Sep 9, 2026
    traded Sep 6, 2026
    		+3dSEC FORM 4

    Evidence

    22
    BJ
    Barry JamesEVP, President, LSG
    BIOBIO.BBIO-RAD LABORATORIES, INC.
    Tax withholding
    		F$142K
    369 sh
    		Sep 5, 2026Sep 9, 2026
    traded Sep 5, 2026
    		+4dSEC FORM 4

    Evidence

    23
    BJ
    Barry JamesEVP, President, LSG
    BIOBIO.BBIO-RAD LABORATORIES, INC.
    Option exercise
    		M—
    1,056 sh
    		Sep 6, 2026Sep 9, 2026
    traded Sep 6, 2026
    		+3dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0002024911-26-000002
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    May 11, 2026
    Published
    May 13, 2026
    Ingested by INSIDER
    Nov 5, 03:59 UTC
    Last re-read
    Nov 5, 03:59 UTC

    Extracted facts

    Filer
    Engelhardt Eva Anette
    Role
    EVP, President, CDG
    Transaction
    Open-market saleAs filed: “S”
    Asset
    BIO-RAD LABORATORIES, INC.
    Ticker
    BIOBIO.B
    Shares
    550
    Price per share
    $246.54
    Value
    $135,597
    Execution date (reported)
    May 11, 2026
    Owned after transaction
    346 shares
    Days from execution to publication
    2

    Calculation

    Value = shares × reported price per share

    • Shares: 550
    • Price: $246.54

    = $135,597

    What this establishes

    Engelhardt Eva Anette filed this Form 4 reporting a open-market sale of BIOBIO.B on May 11, 2026. It became public on May 13, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    EVP, President, CDG
    Engelhardt Eva Anettecik:0002024911
    Issuer
    BIO-RAD LABORATORIES, INC.cik:0000012208

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.

    Source error

    Price history for BIOBIO.B is unavailable.

    An error occurred in the Server Components render. The specific message is omitted in production builds to avoid leaking sensitive details. A digest property is included on this error instance which may provide additional details about the nature of the error.